Aflibercept biosimilar (Amgen)
- Generic Name
- Aflibercept biosimilar (Amgen)
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 49
- Registration Number
- NCT05704725
- Locations
- 🇺🇸
Retina Consultants of Texas - Bellaire Retina Center, Bellaire, Texas, United States
🇺🇸Retinal Consultants of Texas - San Antonio Retina Center, San Antonio, Texas, United States
🇺🇸Retina Consultants of Texas - Austin Retina, Austin, Texas, United States
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
Phase 3
Completed
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 576
- Registration Number
- NCT04270747
- Locations
- 🇨🇦
Clinique d'ophtalmologie des laurentides, Boisbriand, Quebec, Canada
🇵🇱Szpital Sw. Wojciecha, Poznan, Wielkopolskie, Poland
🇸🇰Univerzitna nemocnica Bratislava, Bratislava, Bratislavský Kraj, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath